Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. (2020)
Attributed to:
In vivo pathway analysis to determine the mechanistic role of susceptibility genes for Parkinson's disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2020-038911
PubMed Identifier: 32759251
Publication URI: http://europepmc.org/abstract/MED/32759251
Type: Journal Article/Review
Volume: 10
Parent Publication: BMJ open
Issue: 8
ISSN: 2044-6055